Combined immune checkpoint blockade increases CD8+CD28+PD-1+ effector T cells and provides a therapeutic strategy for patients with neuroblastoma
Soheila Shirinbak, Randall Y. Chan, Shilpa Shahani, Sakunthala Muthugounder, Rebekah Kennedy, Long Hung, G. Esteban Fernández, Michael D. Hadjidaniel, Babak Moghimi, Michael A. Sheard, Alan L. Epstein, Muller Fabbri, Hiroyuki Shimada, Shahab Asgharzadeh
Abstract
) in tumor-draining lymph nodes. Adding chemotherapy before immunotherapy provided significant survival benefit for mice with established tumors receiving anti-PD-1 or dual immune checkpoint blockade. Our findings demonstrate anti-PD-1 and anti-CTLA-4 therapy induces a novel subset of effector T cells, and support administration of induction chemotherapy immediately prior to immune checkpoint blockade in children with high-risk neuroblastoma.
Topics & Concepts
BlockadeImmune checkpointEffectorMedicineCancer researchCytotoxic T cellCD28PD-L1CD8NeuroblastomaImmune systemImmunotherapyImmunologyBiologyInternal medicineReceptorBiochemistryIn vitroGeneticsCell cultureNeuroblastoma Research and TreatmentsCancer Immunotherapy and BiomarkersImmune cells in cancer